echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Chemicals Industry > China Chemical > List of Appointment Time Disclosure Forms for 2020 Annual Reports of Pharmaceutical Equipment Companies

    List of Appointment Time Disclosure Forms for 2020 Annual Reports of Pharmaceutical Equipment Companies

    • Last Update: 2021-11-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [ Star Enterprise of Chemical Machinery Equipment Network ] Looking back on 2020, what kind of transcript can the pharmaceutical equipment industry produce? At present, many listed pharmaceutical equipment companies have disclosed the appointment time for the 2020 annual report, which is basically concentrated around late April.
    Judging from the results of the first three quarters of 2020 that have been disclosed by major pharmaceutical companies, the overall performance is good.

    Chemical machinery and equipment network star enterprise chemical machinery and equipment
    Canaan Technology: The 2020 Annual Report is scheduled to be disclosed on April 17, 2021
     
    Canaan Technology: The 2020 Annual Report is scheduled to be disclosed on April 17, 2021

    Canaan Technology’s performance pre-increase announcement issued on October 30, 2020 shows that the company achieved total operating income of 600 million in the first three quarters of 2020, a year-on-year increase of 68.
    3%; net profit attributable to the parent was 52.
    138 million, a year-on-year increase of 56.
    8%.

     

    As for the reasons for the growth in performance, the company attributed it mainly to the gradual expansion of sales scale and business expansion.

     

      Chutian Technology: The 2020 Annual Report is scheduled to be disclosed on April 24, 2021
     
      Chutian Technology: The 2020 Annual Report is scheduled to be disclosed on April 24, 2021

      On October 24, 2020, Chutian Technology released its third quarterly report for 2020, showing that the company achieved operating income of 1.
    343 billion yuan in the first nine months, a year-on-year increase of 1.
    71%; net profit attributable to shareholders of listed companies was 46.
    376 million yuan, a year-on-year increase 106.
    26%.

     

      The company made the above prediction mainly based on the following reasons: the company actively implemented the result of the strategic deployment of "one vertical, one horizontal and one platform".
    During the reporting period, the overall solutions for medical equipment and the overall pharmaceutical plant project engineering general contracting (EPC) order form grew well.

     

      On the one hand, the company actively carried out product layout within the company, intensified the technological upgrading of old products, as well as the research and development and sales of new products, and further extended and broadened the product chain.
    New products such as isolation systems, sterilization logistics systems, robotic post-packaging systems and intelligent warehousing systems have gradually opened up the market.
    During the reporting period, the growth of new product orders was apparent; on the other hand, the subsidiaries operated well during the reporting period.
    Among them, the operating income of Chutian Huatong Medical Equipment increased by about 47% over the same period of the previous year.

     

      Dong Fulong: Appointment for 2020 Annual Report to be disclosed on April 26, 2021
     
      Dong Fulong: Appointment for 2020 Annual Report to be disclosed on April 26, 2021

      Tofflon disclosed the pre-increasing announcement on October 13, 2020.
    It is expected that the net profit attributable to shareholders of listed companies from January to September 2020 will be between 279 million yuan and 297 million yuan, an increase of 360% to 390% year-on-year.

     

      The main reason for the change in performance was that during the reporting period, the company actively responded to customer needs and effectively guaranteed the completion of the system project delivery plan by focusing on the development strategy of “systematization, digitization, and digitization”; Technical cooperation and exchanges in the science of pharmaceutical manufacturing and scientific manufacturing of pharmaceutical machinery; continue to implement the concept of precise management, implement digital transformations, and improve cost control; at the same time, the company's new products and new markets in various business segments over the years have gradually shown results, which belong to listed companies The net profit of shareholders is expected to increase by 360%-390% over the same period of the previous year.

     

      Xinlai Material: The 2020 Annual Report is scheduled to be disclosed on April 27, 2021
     
      Xinlai Material: The 2020 Annual Report is scheduled to be disclosed on April 27, 2021

      On October 26, 2020, Xinlai Yingcai disclosed the report for the third quarter of 2020.
    The announcement showed that the company achieved revenue of 980 million yuan in the first nine months of 2020, a year-on-year decrease of 1.
    52%; net profit attributable to shareholders of listed companies was 62.
    665 million yuan , An increase of 30.
    73% year-on-year.

     

      Xinhua Medical: Appointment for 2020 Annual Report to be disclosed on April 30, 2021
     
      Xinhua Medical: Appointment for 2020 Annual Report to be disclosed on April 30, 2021

      Xinhua Medical’s 2020 third quarter report released on October 31, 2020 shows that the company achieved operating income of 6.
    53 billion yuan in the first nine months, a year-on-year increase of 3.
    43%; net profit attributable to shareholders of listed companies was 213 million yuan, a year-on-year decrease of 73.
    45%.
    The company attributed the change in performance to the fact that in 2019, the company sold 8.
    2041% of the equity of Suzhou Changguanghua Doctor Biomedical Engineering Co.
    , Ltd.
    ; the company's wholly-owned subsidiary Huatuo Development Co.
    , Ltd.
    transferred 60% of Vista Medical Co.
    , Ltd.
    The company’s investment income has increased significantly.

     

      Concluding remarks
     
      Concluding remarks

      In summary, in the first three quarters of 2020, most companies in the pharmaceutical equipment industry have achieved significant growth in revenue, mainly due to the impact of special periods, the increase in orders and the increase in sales revenue.
    At the same time, many companies In the context of fierce market competition, through active development of new products, expansion of new markets and new businesses, and strengthening of cost control, the performance has achieved good development.
    The industry predicts that the overall annual report card of the pharmaceutical equipment industry in 2020 will also remain dazzling.

     

      Original Title: List of Appointment Time Disclosure Forms for the 2020 Annual Reports of Pharmaceutical Equipment Companies
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.